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Detection of cystic fibrosis transmembrane conductance regulator (CFTR) protein is usually a difficult task to accomplish due to the low
levels of expression and high turnover that this membrane protein is submitted to in the cell. Common biochemical methods can be used for
the detection of CFTR but several critical points must be taken into account. The scope of this article is to outline biochemical methods
commonly used to assess CFTR expression, processing and membrane localization.
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1. Introduction membrane glycoprotein that is mainly expressed at theCystic fibrosis (CF) transmembrane conductance regula-
tor (CFTR) protein, product of the CF gene, is an integral1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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Abbreviations: Ab, antibody; AP, alkaline phosphatase; ABC, ATP-
binding cassette (transporter); DAB, 3,3-diaminobenzidine tetrahydrochlor-
ide; DOC, sodium deoxycholate; DTT, dithiotreitol; ELISA, enzyme-linked
immunosorbant assay; Endo H, endoglycosidase H; ER, endoplasmic
reticulum; HRP, horseradish peroxidase; IP, immunoprecipitation; NP-40,
nonidet P-40; PAGE, polyacrylamide gel electrophoresis; 4-PB, 4-phenyl
butyrate; PBS, phosphate-buffered saline; PNGase F, N-glycosidase F; R,
(domain) regulatory (domain); SDS, sodium dodecyl sulphate; TM,
transmembrane domain; WB, Western blot.
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E-mail address: cfarinha@igc.gulbenkian.pt (C.M. Farinha).apical membrane of epithelial cells where it functions as a
cAMP-stimulated chloride (Cl) channel [1]. CFTR, a
member of the ATP-binding cassette (ABC) transporter
superfamily (ABCC7), has 1480 aminoacid residues and
comprises several domains: two transmembrane domains
(TMs 1 and 2, each one with six membrane spanning
segments), two nucleotide binding domains (NBDs 1 and
2) and a large regulatory (R) domain [1].
Like other glycoproteins, CFTR is synthesized on endo-
plasmic reticulum (ER)-associated ribosomes and core-oli-
gosaccharide chains are attached to the protein co-
translationally at the asparagines (N) residues 894 and 900
located in the 4th extracellular loop [2]. A large proportion
of CFTR is degraded from the ER. The remaining areed by Elsevier B.V. All rights reserved.
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polypeptidic chain undergoes different post-translational
modifications at its glycidic residues to produce the fully
glycosylated mature form. Monitoring the glycosylation
state of CFTR is thus a convenient way to follow the
intracellular processing of CFTR, and it allows to distin-
guish the wild-type (wt) protein from the several processing
mutants. According to its glycosylation status, one can
distinguish three diferent forms of the CFTR: (1) the newly
synthesized non-glycosylated polypeptidic chain (only bio-
chemically detected following treatment with glycosidases),
known as band A (130 kDa); (2) the ER core-glycosylated
form of the protein, known as band B (150 kDa); and (3) the
fully glycosylated mature form of CFTR, known as band C
(170–180 kDa) [3].
Soon after cloning of the CF gene in 1989 [4–6] and
prediction of the respective protein structure [4], great
interest arouse in its biochemical detection by Western blot
(WB) or by immunoprecipitation (IP). However, this is not
an easy task due to its very low levels of expression in
native tissues and low sensitivity/specificity of anti-CFTR
antibodies (Abs) (see Ref. [7]). Since the design of the
experimental protocol to biochemically detect CFTR ex-
pression is also critical, we review here these protocols
(with the details being given elsewhere [8]).2. Methods to assess CFTR expression
Generally, the biochemical methods of WB and IP aim at
determining the presence of a given protein in a sample
under study, or to specifically determine its relative abun-
dance or molecular mass (and hence, its glycosylation status
and subcellular localization). The latter is particularly im-
portant to assess the effect of mutations on processing,
which is generally carried out in heterologous expression
systems, due to the low levels of endogenous expression in
most tissues. Production of a mutant cDNA cloned into an
mammalian expression vector is thus a valuable tool to
analyze properties of CFTR mutants, namely in terms of
folding, structure and function.
2.1. Site-directed mutagenesis on CFTR-cDNA
For the rapid introduction of point mutations, small
deletions/insertions into a sequence (i.e., CFTR cDNA
cloned in a given expression vector) there is a commer-
cially available site-directed mutagenesis technique
(QuikChangeR, Catalog #200518/9; Stratagene, La Jolla,
CA, USA) that is easy to perform and a high success rate.
The detailed protocol is detailed elsewhere [9]. The method
is generally based on the use of two complementary oligo-
nucleotide primers of 25–45 nucleotides, containing the
desired mutation in the middle region, flanked by unmodi-
fied nucleotide sequences. Pfu Turbo DNA polymerase,
under specific cycling parameters, extends these primers inboth directions and generates, with high fidelity, a mutant
plasmid, although still containing nicks. To check for the
mutagenesis efficiency, the amplified product is analyzed on
agarose gel, following hydrolysis with DpnI, which is
specific for methylated and hemi-methylated DNA thus
removing the parental plasmid. The nicked mutant plasmid
is used to transform competent Escherichia coli cells that
efficiently repair the nicks and amplify it. The presence of
the desired mutation should be confirmed by sequencing.
The mutant CFTR cDNA plasmid, may be subsequently
used to transiently or stably transfect mammalian cells lines
which will thus produce the mutant protein.
2.2. Detection of CFTR protein expression in human and
mouse tissues and in cultured cells by Western blotting
The detailed protocol of WB is described in detail
elsewhere [8]. It can be used to check the presence of CFTR
protein or its relative abundance and molecular mass.
In general, WB is robust, simple and sensitive. However,
it is elusive when applied to the detection of CFTR in native
tissues, due to the low abundance of this protein. Other
reasons account for the unsatisfactory biochemical detection
of CFTR in cell lines, like the frequent lack of sensitivity
and specificity of anti-CFTR Abs [7]. The outlined WB
protocol [8] is simple and reproducible when applied to
samples of cultured cells. For native tissues (human or
mouse), however, additional manipulations are recommen-
ded, including isolation of membranes by differential cen-
trifugation to increase CFTR concentration and incubation
of samples in excess cold saline and a cocktail of protease
inhibitors, prior to protein extraction.
WB is composed of five main steps: (1) preparation of
CFTR sample (cell lysis); (2) resolution by sodium dodecyl
sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE);
(3) transfer of separated proteins onto a membrane (nitro-
cellulose or PVDF); (4) staining the blot to assess efficiency
of protein transfer (can be omitted); and (5) CFTR detection
with a specific antibody (Ab).
After washing cells with PBS, lysis is performed in gel
electrophoresis sample buffer (containing 5% (w/v) SDS
and 0.5 mM DTT). It is very important to avoid boiling the
samples. Instead, incubation at 55 jC for 15 min is carried
out. Chromosomal DNA is sheared to lower viscosity by
passing the sample sequentially through 22- and 27-gauge
(ga.) needles. After protein quantification (Lowry), about
30–50 Ag (depending on expression levels of cell line under
analysis) of total protein per sample are separated by SDS-
PAGE on a 7% (w/v) polyacrylamide resolving gel.
After electrophoresis, a common wet-transfer electro-
blotting procedure is carried out. Prior to CFTR detection,
the membrane is blocked (5% (w/v) skimmed dry milk;
0.1% (v/v) Tween 20 in PBS) to prevent non-specific
adsorption of the Abs. Indirect detection is performed by
incubation with primary anti-CFTR Ab, and then with a
labelled (e.g., with horseradish peroxidase, HRP) secondary
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chemiluminescence approach. Alternatively, an alkaline
phosphatase (AP)-conjugated secondary Ab may be used
and detection is performed with 3,3-diaminobenzidine tet-
rahydrochloride (DAB).
Immunostaining specificity can be confirmed by ade-
quate controls and purified Abs. Polyclonal anti-CFTR Abs
raised against rodent or human CFTR peptides should be
affinity-purified [7] and ideally samples from CFTR-null
mice (or patients with two stop mutations) should be
included. Formation of high molecular mass aggregates is
minimized if lysis is performed for a longer period (30 min)
at room temperature (RT).
2.3. CFTR immunoprecipitation
The complete protocol of IP [8] consists in partial
isolation of CFTR protein, from total lysates. IP can be
used to determine the molecular mass, to study protein/
protein associations [10], monitor the appearance of co/post-
translational modifications and, when coupled to a pulse-
chase protocol, to determine the protein half-life.
The IP protocol comprises three different steps: (1)
preparation of cell lysate; (2) pre-clearing the lysate of
non-specific background (this step can be omitted); and
(3) formation and purification of the antigen–Ab complex.
The lysis method depends on the cell type under study
and the final experimental purpose. No single buffer has
applicability to all purposes. In general, lysis conditions
should be as gentle as possible to retain the epitope(s) to be
recognized. The most common cell lysis buffer is RIPA. It
releases most soluble cytoplasmic and nuclear proteins, but
also disrupts most protein–protein interactions.
Pre-clearing consists in removal of proteins non-specif-
ically bound to the immune complex or to protein A (or G)
beads prior to IP. Pre-clearing can be omitted if non-specific
interactions are not expected in large extent or if, as for
CFTR, in vitro degradation of the target protein (and thus
time) is critical.
Theoretically, the Ab–CFTR complex formation is the
simplest step in the protocol. The Ab is added to the
lysate binding to CFTR present. Then protein A (or G)
beads are added. After mixing and incubation for f4 h at
4jC, proteins not bound to the beads are washed out
with lysis buffer. The Ab amount used is critical, depend-
ing on the Ab itself (its avidity) and on the titre of the
serum or ascites fluid. Recommended dilutions for anti-
CFTR Abs are reviewed elsewhere [7]. The IP reaction
volume is also important, if too small, unspecific binding
occurs and if too large, CFTR-Ab binding becomes
excessively slow.
Elution of Ab-bound proteins is also critical, as drastic
procedures like heating or shaking will diminish the final
yield. Elution can be performed by Laemmli application
buffer (‘‘cracking buffer’’) that includes SDS, a reducing
agent [dithiotreitol (DTT) or h-mercaptoethanol] and acomponent to increase sample density for gel loading
(e.g., glycerol or sucrose).
After gel electrophoresis, detection of CFTR is performed
by Coomassie or silver staining (see Ref. [11]) if the objective
is simply the detection (presence/absence) of specific CFTR
processing forms (bands B and C). To increase sensitivity,
cells can be radio-labelled by, e.g., [35S]methionine and/or
[35S]cysteine and IP performed as above.
Radio-labelling can also used for the determination of
CFTR half-life by a pulse-chase performed prior to IP. The
radioactive aminoacid is added to the medium for, e.g., 20
min (‘pulse’), to be incorporated into nascent proteins. The
radioactive medium is then replaced by another with excess
of unlabelled aminoacid. IPs are then performed at different
times (‘chase’) after medium replacement (e.g., 0, 0.5, 1, 2
and 3 h). The determined rate of radioactivity loss is a
measure of CFTR turnover.
WB detection of immunoprecipitated CFTR or phosphor-
ylation (with 32P) of CFTR prior to elution can be used for
enhanced IP sensitivity. The latter is to be used mainly for
accurate quantification of steady-state level of bands B and
C. It makes use of the presence of several consensus
phosphorylation sites for cAMP-dependent protein kinase
A (PKA) in the R domain. However, the level of in vivo
phosphorylation affects the results.3. Detection of CFTR expression at the plasma
membrane
Cell-surface biotinylation is useful to distinguish cell
surface from intracellular proteins, thus, allowing to study
CFTR expression exclusively at the plasma membrane. A
non-cleavable form of biotin reagent (EZ-Link Biotin-LC-
hydrazide; Pierce Rockford, IL, USA) is chosen over
cleavable biotin reagent (e.g., EZ-Link Sulfo-NHS-S-S-
biotin, Pierce), mainly for two reasons: (a) Biotin-LC-
hydrazide has binding affinity to carbohydrates present on
the 4th extracellular loop of CFTR (see Introduction), and
(b) disulfide bonds present in Sulfo-NHS-S-S-biotin (which
has affinity for amino groups) cannot be cleaved by reduc-
ing agents as efficiently as claimed by the manufacturer.
This may lead to contamination of biotinylated (surface)
proteins with the unbiotinylated (intracellular) proteins.
However, unlike Sulfo-NHS-S-S-biotin, Biotin-LC-hydra-
zide is cell permeable. Thus, out the biotinylation protocol
should be carried out on ice (with ice-cold buffer) to prevent
its intracellular incorporation. Since Biotin-LC-hydrazide is
non-cleavable, WB only allows indirect measurement of
surface expressed CFTR.
Cells stably expressing (wt or mutant) CFTR [11] are
grown to 70% confluency and then either directly analysed
or treated with 5 mM 4-phenyl sodium butyrate (4-PB) for
24–60 h to up-regulate CFTR expression [12,13]. Cells
expressing processing mutants, like F508del, should be
incubated with 4-PB at 27 jC to induce surface expression
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Working Group on CFTR Expression website [8]. Briefly,
cell monolayers are washed 3 with PBS/c-m (i.e., PBS
with 0.1 mM CaCl22H2O; 1 mM MgCl2) and incubated for
30 min with periodate solution (10 mM NaIO4 in PBS/c-m)
to oxidize the carbohydrate moieties on cell surface. Cells
are washed again as above, followed by a single wash
with acetate buffer (100 mM sodium acetate; 0.1 mM
CaCl22H2O; 1 mM MgCl2). All steps are carried out on
ice and in the dark with ice-cold buffer, unless otherwise
stated. Cells are incubated with 2 mM biotin-LC-hydrazide
for 30 min. Unbound biotin is removed by three PBS-c/m
washes. Cell lysates are prepared as above for WB [8].
Biotinylated (surface) proteins are irreversibly extracted
with streptavidin immobilized on 4% beaded agarose
(SA). Simultaneously, an aliquot of lysate is also processed
with uncoated control agarose beads (CN). Supernatants
from SA beads contain only unbiotinylated (intracellular)
proteins, whereas supernatants from CN beads contain both
surface and intracellular proteins.
Thirty micrograms of total protein supernatants from SA
or CN beads are analysed by WB (see above). The scanned
CFTR signal from SA beads is subtracted from CN beads
signal to indirectly determine the surface expressed CFTR.
It is essential that SA beads completely extract the
biotinylated proteins to avoid any contamination of unbio-
tinyalted (intracellular) proteins with that of biotinylated
(surface) proteins. Following WB the membrane is stripped
off of the Ab [8] and incubated with streptavidin–HRP (4
Ag conjugate/ml). Colour is developed by DAB and the
reaction stopped by several washes with water. When
efficiently extracted, the SA beads sample does not evidence
any bands, whereas the CN beads sample evidences a
number of bands, i.e., all biotinylated proteins [12,13].
Biotinylated proteins can also be visualized immediately
after protein transfer to nylon membrane (see above).
An enzyme-linked immunosorbant assay (ELISA) vari-
ant of this biotinylation protocol has also been described for
CFTR [8]. This has the major advantage of being performed
in SA-coated 96-well micro plates, thus allowing the rapid
screening of, e.g., on CFTR processing mutants. A detailed
protocol is found elsewhere[8]. Briefly, cells are surface
biotinylated and lysates immunoprecipitated using one anti-
CFTR Ab. Biotinylated-CFTR then binds to streptravidin-
coated ELISA plates and detected by one anti-CFTR Ab and
AP-or HRP-conjugated secondary Ab. Colour is developed
by adding a substrate of HRP specially designed for ELISA
(e.g., ABTSR from Roche), and spectrophotometically read
at 405 nm. Controls include assays where primary or
secondary Abs are omitted.4. Membrane preparation and CFTR deglycosylation
The isolation of microsomal membrane vesicles from
BHK-21 cells stably expressing CFTR is based on aprotocol developed earlier for CHO cell fractionation [14].
The protocol discussed here is described elsewhere in detail
[8] and it is similar to that employed for CFTR channel
gating studies in lipid bilayers [15,16]. CFTR is enriched in
membranes compared to cell lysates, therefore it is easier to
detect (by IP or WB) in membrane preparations. These have
been used in many applications, where increased amounts of
CFTR, but not the purified protein, are required, such as
photo-labelling of CFTR by 8-azido-ATP [17]. Furthermore,
membrane vesicles are commonly utilized for the charac-
terization of wt and mutant CFTR in single-channel meas-
urements [16,18,19].
The difference in molecular mass between fully com-
plex glycosylated and core-glycosylated protein can be
detected by WB, as described above. However, final proof
of the gycosylation status of CFTR can be obtained by
tests with specific glycosidases. Peptide N-Glycosidase F
(PNGase F, N-Glycanase) deglycosylates core-and com-
plex-glycosylated CFTR completely. Endoglycosidase H
(Endo H) only removes unprocessed core-oligosaccharide
chains.
The preparation of microsomal membranes followed by
enzymatic deglycosylation is a straightforward procedure to
identify the glycosylation state of CFTR. The following
precautions should be considered to obtain good results.
Before starting the membrane preparation, cell culture
dishes should be placed on ice and kept there (or at 4 jC)
during all subsequent steps. The homogenization of the
microsomal pellet is facilitated by brief sonication.
Prior to deglycosylation, proteins are usually denaturated
by SDS at 95 jC. However, like other integral membrane
proteins, CFTR has a tendency to form aggregates upon
boiling and therefore samples should not be treated this way
(see above, WB protocol). CFTR is also very sensitive to
proteolytic degradation, thus use of protease-free deglyco-
sylation enzymes are recommended.
The detailed protocols for membrane preparation and
protein deglycosylation are given elsewhere [8]. Briefly,
after washing with ice-cold PBS,f 80–95% confluent cells
are scraped into PBS with 1 protease inhibitors (Ag/ml): 1
leupeptin; 2 aprotinin; 50 Pefabloc; 121 benzamidine; 3.5
E64. Cells are collected in 50-ml tubes by centrifugation at
1000 g for 5 min at 4 jC. Cells are resuspended in lysis
buffer (10 mM HEPES pH 7.2; 1 mM EDTA; 1 protease
inhibitors) and incubated on ice for 10 min. Cell lysis is
performed with a pre-cooled Dounce cell homogenizer (8–
10 strokes) and lysis is monitored with a microscope after
trypan blue stain. An equal volume of sucrose buffer (10
mM HEPES pH 7.2; 500 mM sucrose; 1 protease
inhibitors) is added and the same number of strokes repeat-
ed, as above. Cells are centrifuged at 6000 g, 10 min at
4 jC to pellet debris and organelles and the supernatant is
centrifuged again at 100,000 g, for 30 min at 4 jC to
collect membranes.
For Endo H digestion, 20–100 Ag membrane protein is
solubilized in 50–100 Al Endo H incubation buffer [8] with
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added to the reaction mixture and incubated 3 h to overnight
at 37 jC.1
For PNGase F digestion, a solution of 20–100 Ag protein
in 50–100 Al PNGase F incubation buffer (20 mM sodium
phosphate pH 7.5) with 1 protease inhibitors is prepared.
A 1/20 volume of denaturation solution (2% (w/v) SDS, 1
M h-mercaptoethanol) and of 15% (w/v) NP-40 are added)
are added. The deglycosylation starts by the addition of 4
Al (10 mU) of PNGase F (GLYKOR/ProZyme; San Lean-
dro, CA, USA) to the reaction mixture and samples are
incubated 3 h to overnight at 37 jC.
If necessary the deglycosylated samples may be precip-
itated and concentrated by the addition of 4 volumes of cold
ethanol ( 20 jC). The nonglycosylated, core-glycosylated
and complex-glycosylated form of CFTR can be separated
by SDS-PAGE and subsequently detected by WB (see
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